Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2015 / Article
Special Issue

Dietary Polyphenols and Their Effects on Cell Biochemistry and Pathophysiology 2014

View this Special Issue

Research Article | Open Access

Volume 2015 |Article ID 958217 | https://doi.org/10.1155/2015/958217

Hao Han, Peipei Yan, Li Chen, Cheng Luo, Hui Gao, Qianchun Deng, Mingming Zheng, Yong Shi, Liegang Liu, "Flaxseed Oil Containing α-Linolenic Acid Ester of Plant Sterol Improved Atherosclerosis in ApoE Deficient Mice", Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 958217, 17 pages, 2015. https://doi.org/10.1155/2015/958217

Flaxseed Oil Containing α-Linolenic Acid Ester of Plant Sterol Improved Atherosclerosis in ApoE Deficient Mice

Academic Editor: David Vauzour
Received17 Sep 2014
Accepted05 Jan 2015
Published09 Jun 2015


Plant sterols (PS) have potential preventive function in atherosclerosis due to their cholesterol-lowering ability. Dietary α-linolenic acid in flaxseed oil is associated with a reduction in cardiovascular events through its hypolipidemic and anti-inflammation properties. This study was designed to evaluate the effects of flaxseed oil containing α-linolenic acid ester of PS (ALA-PS) on atherosclerosis and investigate the underlying mechanisms. C57BL/6 mice were administered a regular diet and apoE knockout (apoE-KO) mice were given a high fat diet alone or supplemented with 5% flaxseed oil with or without 3.3% ALA-PS for 18 weeks. Results demonstrated that flaxseed oil containing ALA-PS was synergistically interaction in ameliorating atherosclerosis as well as optimizing overall lipid levels, inhibiting inflammation and reducing oxidative stress. These data were associated with the modification effects on expression levels of genes involved in lipid metabolism (PPARα, HMGCR, and SREBPs), inflammation (IL-6, TNF, MCP-1, and VCAM-1), and oxidative stress (NADPH oxidase).

1. Introduction

Atherosclerosis is the primary cause of cardiovascular diseases (CVD), which is one of the leading causes of mortality and morbidity in the world [1]. Although the precise mechanisms for atherosclerosis have not been fully elucidated, an elevated concentration of low-density lipoprotein cholesterol (LDL-C) is a well-established independent risk factor for atherosclerosis [2]. In addition, LDL oxidation has been illustrated as one of the initial steps of atherogenesis [3]. Therefore, dietary and pharmacologic interventions targeted at lowering LDL-C are very important elements for atherosclerosis prevention.

The pathophysiological significance of plant sterols (PS), one kind of natural compounds presenting in plant oils, nuts, cereals, and legumes, has been intensively discussed in previous reports. It has been reported that consumption of 2 g/day PS could reduce LDL-C by 10–15% in about 90% of individuals [4]. Another previous publication also demonstrated that supplementation of PS in diet may have decreased LDL-C level (10%) for reducing risk of cardiovascular (10–20%) [5]. However, PS was not observed to have any beneficial effect on triacylglycerol (TG) and high-density lipoprotein cholesterol (HDL-C) [6], two important independent factors for cardiovascular disease [7, 8]. In addition, purified PS was shown to have low intestinal bioavailability and poor solubility in diet. Because n-3 polyunsaturated fatty acids (PUFAs) have potent hypotriglyceridemic and HDL-C elevation effects, PS has been recently esterified by fish oil fatty acids to obtain final product plant sterols esters which have overall beneficial effects on lipids [9], well bioavailability, and extensive solubility in fat. Therefore, plant sterols esters can be incorporated into fatty foods, such as margarines, yoghurt, and spreads [10]. However, fish oil fatty acid is insufficient supply nutrient, and margarines, yoghurt, and spreads are not the main food in China. α-Linolenic acid (ALA, C18:3n-3), the major n-3 fatty acid, widely exists in flaxseed oil which is a traditional edible oil in China. As the precursor of longer chain n-3 PUFA (EPA and DHA), ALA had good effects on TG reduction and HDL-C elevation [11]. More importantly, a large number of epidemiological evidences showed that consumption of ALA could protect against CVD [12, 13]. These data suggest that ALA may be a perfect vehicle for PS esterification and the combination treatment may synergistically improve atherosclerosis. Meanwhile, as one of the high frequency and largely consumed oils in Chinese daily cooking, flaxseed oil is a good way for Chinese to get enough PS. However, the efficiency of this novel flaxseed oil fortified with α-linolenic acid ester of plant sterol (ALA-PS) has not been shown.

In the current study, we detected the effects of dietary flaxseed oil containing ALA-PS on atherosclerosis in apoE-KO mice and investigated the underlying molecular mechanisms.

2. Materials and Methods

2.1. Study Design

A total of 42 male apoE-KO mice and 14 wild type C57BL/6 mice (6 weeks of age, 15–19 g) were purchased from Peking University Resources Centre (Permission number: SCXK 2011-0012). After one-week acclimatization period, 14 wild type C57BL/6 mice were assigned to control group and given normal chow. 42 male apoE-KO mice were randomly divided into HFD-, FO-, and FO+ALA-PS-treated groups matched with their mean body weight and plasma total cholesterol levels as previously published methods [14]. HFD group was given a high fat diet containing of 21% fat and 0.15% cholesterol [15]. This high fat diet was further supplemented with 5% (w/w) flaxseed oil for FO group; a combination of 3.3% (w/w) ALA-PS (provided 2% PS) mixture with flaxseed oil which provided equivalent ALA to FO group was added to the high fat diet and used for ALA-PS group. The flaxseed oil was manufactured by Inner Mongolia Caoyuan Kanghen Food Co. Ltd. (Hohhot, China) and contained 57.82% ALA (% of total fatty acids). Plant sterol (β-sitosterol 77%, campesterol 17%, and stigmasterol 5%) was provided by BASF Co. Ltd. (Shanghai, China). ALA (α-linolenic acid 80%, linoleic acid 15%, and oleic acid 5%) was purchased from Henan Linuo Biochemical Co. Ltd. (Anyang, Henan, China). The ALA-PS was synthesized by Oil Crops Research Institute, Chinese Academy of Agricultural Sciences, Wuhan, China (Wuhan, China) using PS and ALA mentioned above [16]. The animals were maintained in constant temperature-controlled rooms (°C) with controlled lighting (12 h light-dark cycles). The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and was approved by Tongji Medical College Council on Animal Care Committee.

After 18 weeks, three animals in each group were randomly selected for en face aorta and aortic sinus Oil-Red O staining to observe their pathological changes and lipid deposition. The remaining animals were feed-deprived for 8 h, anesthetized with ketamine HCl (50 mg/kg)/xylazine (10 mg/kg), and subsequently killed by cervical dislocation. Blood was collected and centrifuged for 20 min at 5000 g at 4°C and then stored at −80°C. Aorta and liver were excised, immediately frozen in liquid nitrogen, and stored at −80°C until use.

2.2. Histology and Morphometry Evaluations of Atherosclerotic Lesions

For en face analysis, the aorta from the ascending arch to the iliac bifurcation was cleaned of peripheral tissue, opened longitudinally, pinned flat, and stained with Oil-Red O. Images were captured with Canon IXUS 220 HS camera.

The heart samples were embedded in tissue freezing medium O.C.T. and sectioned into consecutive 8 μm thick sections at −20°C. The distal end of the aortic sinus was recognized by the disappearance of the three aortic valve cusps. Every sixth section was stained with Oil-Red O and digitally photographed under magnification (×40).

Images were analyzed using Image-Pro Plus (IPP) software. The lesion area index was calculated as the percentage of aortic lumen area covered by atherosclerotic lesions.

2.3. Immunohistochemistry Assay

Aortic arch cross-sections were immunostained with CD68 (1 : 400; ab955, Abcam Limited), Ly-6C (1 : 200; sc-52650, Santa Cruz Biotechnology), and α-smooth muscle actin antibodies (1 : 500, A 5228, Sigma-Aldrich) to detect macrophages, Ly-6C-positive macrophages, and smooth muscle cells. After washing, sections were incubated with anti-rat and anti-mouse horseradish peroxidase-conjugated secondary antibodies at 1 : 200 dilutions (CST). Immunocomplexes containing CD68, Ly-6C, and α-smooth muscle actin antibodies were detected using diaminobenzidine tetrahydrochloride dihydrate substrate (DAB; Sigma). The sections were digitally photographed under magnification (×200).

2.4. Determination of Lipid Parameters in Serum and Liver

The concentrations of TC, TG, LDL-C, and HDL-C in serum and liver were measured by enzymatic colorimetric assays using commercially available detection kits (Biosino Biotechnology Co., Ltd., Beijing, China).

2.5. Measurement of Inflammation Cytokines in Plasma

The levels of interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) in plasma were measured by enzyme linked immunosorbent assays using commercially available detection kits (R&D Systems, USA.).

2.6. Determination of Oxidative Stress Parameters in Serum and Liver

The concentrations of glutathione (GSH) were measured according to its reaction with 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) into 2-nitro-5-thiobenzoic acid (TNB), following deproteinization by 5% trichloroacetic acid [17]. Malondialdehyde (MDA), an index of lipid peroxidation, was measured by using thiobarbituric acid colorimetry slightly modified by Ohkawa et al. [18]. The contents of GSH and MDA in liver were standardized by protein concentration measured by the Bio-Rad Protein Assay Kit (USA).

2.7. Evaluation of ROS Level in Aorta of Mice

Dihydroethidium (DHE) (Molecular Probes, Eugene, OR, USA) was used for in situ detection of reactive oxygen species (ROS) in the aorta of mice. Fresh cross-sections (5 μm) of unfixed but frozen aorta were immediately incubated with 5 M DHE at 37°C for 15 min in a humidified chamber. Fluorescence level was then visualized with a fluorescence microscope. Fluorescence intensities in randomly selected areas of the images were quantified by using the IPP image analysis software.

2.8. Real-Time RT-PCR Analysis

Total RNA was isolated from the stored frozen liver, aorta tissue, and fresh blood monocytes using the Trizol reagent (Invitrogen, 154 Carlsbad, CA, USA). Messenger RNA (mRNA) expression was quantified by using specific oligo primers and SYBRGreen-based qRT-PCR kit (TaKaRa Biotechnology Co., Ltd., Dalian, China) in 7900HT instrument (Applied Biosystems, Forster, CA, USA). The specificity of the product was assessed from melting curve analysis. Gene expressions were determined using the method. The mRNA of β-actin was quantified as an endogenous control. Gene expressions are presented as fold change relative to control. Quantitative real-time PCR primers were as shown in Table 1.

GeneForward primerReverse primer


2.9. Western Blot Analysis

Thoracic aorta, liver tissues, and blood monocytes were homogenized and lysed in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, and 0.1% SDS). Tissue lysates with equal protein amounts were subjected to western blotting. The protein was separated by 10% SDS-polyacrylamide gel and then transferred onto a PVDF membrane. The membranes were incubated with specific primary antibodies under overnight at 4°C after blocked with 5% nonfat milk solution. Then the target proteins were incubated with the species-specific secondary antibodies conjugated to horseradish peroxidase. Immunoreactive bands were detected by means of an ECL plus Western Blotting Detection System (Amersham Biosciences, Little Chalfont, UK) according to the manufacturer’s instructions. Quantitative analysis of the relative density of the bands in western blots was performed by Quantity One 4.62 software (Bio-Rad, Hercules, CA, USA). Data were corrected for background standardized to β-actin as optical density (OD/mm2). Primary antibodies were as follows: monoclonal anti-β-actin (Sigma), rabbit anti-SREBP2 (Abcam Limited), rabbit antibody anti-SREBP1 (Abcam Limited), rabbit anti-PPARα (Abcam Limited), rabbit anti-HMGCr (Abcam Limited), rabbit anti-IL-6 (Cell Signaling Technology), mouse anti-TNF alpha (Abcam Limited), rabbit anti-VCAM1 (Abcam Limited), rabbit anti-MCP1 (Abcam Limited), mouse anti-IL-1β (Cell Signaling Technology), rabbit anti-p22-phox (Santa Cruz), rabbit anti-p47-phox (Merck Millipore Corporation), rabbit anti-p67-phox (Merck Millipore Corporation), rabbit anti-gp91-phox (Abcam Limited), anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology), and anti-mouse IgG HRP-linked antibody (Cell Signaling Technology).

2.10. Statistical Analysis

Results are expressed as means ± SD, and was considered significant. Statistical analyses of data were performed using one-way analysis of variance with SPSS 12.0 software package (SN: 59245 46841 40655 89389 09859 21671 21957 29589 12).

3. Results

3.1. FO+ALA-PS Ameliorated Atherosclerosis Induced by HFD in Mice

En face analysis of aorta revealed atherosclerotic lesion formation with the aid of Oil-Red O staining. As representative results showed in Figure 1(a), compared with control, a significantly atherogenic action was induced in apoE-KO mice given HFD while the lesions in the FO and FO+ALA-PS groups were obviously decreased. Quantitative analysis of the atherosclerotic lesions in the aortas of mice (Figure 1(b)) demonstrated statistically smaller lesion size in FO+ALA-PS-treated animals than those in FO-treated mice (% versus %).

Cross-sectional analysis of atherosclerotic development at the aortic sinus revealed lipid deposition with the aid of Oil-Red O staining. Representative images were shown in Figure 1(c). The control group was shown to have little lipid deposition. Atherosclerotic lesions at the aortic sinus were extensive following HFD feeding, while FO and FO+ALA-PS treatment groups had much less lipid deposition. The extent of atherosclerotic development at the aortic sinus was quantified as a percentage of aortic cross-sectional luminal area occupied by Oil-Red O-stained lipid deposits. As illustrated in Figure 1(d), the addition of flaxseed oil to an atherogenic diet significantly inhibited the development of atherosclerotic lesions at the aortic sinus, and a further improvement effect was observed in FO+ALA-PS intervention group (% versus %). These results indicated that the addition of ALA-PS markedly strengthened the antiatherogenic properties of flaxseed oil in apoE-KO mice.

3.2. Anti-Inflammatory and Antiproliferative Actions of FO+ALA-PS

Inflammation is now considered to be an important mechanistic process involved in atherosclerosis, and markers of inflammation are also detected as a function of the dietary interventions. The macrophage marker CD68 and Ly-6C have been used as an indicator of inflammatory reactions associated with atherosclerosis. As shown in Figures 2(a) and 2(b), mice fed HFD were characterized by increased infiltration of macrophages and Ly-6C monocyte compared with control. Flaxseed oil supplementation alone did not reduce macrophages, but when included with ALA-PS, flaxseed oil was capable of mitigating the accumulation of macrophages.

In addition, atherosclerotic plaque is generated partly by proliferation and migration of vascular smooth muscle cells (VSMC), and α-actin can be used as a marker of VSMC proliferation within the vessel wall. As shown in Figure 2(c), intimal VSMC contents were pronounced in mice of HFD and FO groups while dietary FO+ALA-PS inhibited proliferation and migration of VSMC.

3.3. Combined Treatment with FO+ALA-PS Improved Lipid Metabolism

The intervention of flaxseed oil alleviated the rise of TG induced by HFD in serum and liver while a much larger decrease in TG was observed in FO+ALA-PS group. Although flaxseed oil feeding alone elevated serum HDL-C, it had no effect on LDL-C and TC. Combination treatment not only apparently reduced LDL-C and TC but also increased the concentration of HDL-C (Table 2). To investigate the underlying molecular mechanism by which dietary FO+ALA-PS modulates lipid metabolism, gene and protein expressions of the major factors involved in hepatic cholesterol homoeostasis, fatty acid catabolism, and synthesis were detected. As illustrated in Figure 3, mRNA and protein expressions of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and sterol regulatory element binding protein 2 (SREBP-2) were found to be statistically decreased in FO+ALA-PS-treated but not FO-treated animals, as compared to those in HFD-fed animals. In addition, flaxseed oil intervention elevated peroxisome proliferator-activated receptor α (PPARα) and reduced sterol regulatory element-binding protein 1c (SREBP-1c), respectively. A more pronounced effect was achieved by FO+ALA-PS application.


Serum TC (mmol/L)1.72 ± 0.24 20.77 ± 5.00a16.04 ± 4.59a11.33 ± 3.15abc
Serum TG (mmol/L) 0.91 ± 0.15 2.27 ± 0.40a1.83 ± 0.42ab1.39 ± 0.41abc
Serum LDL-C (mmol/L) 0.31 ± 0.12 12.16 ± 3.11a10.24 ± 2.32a4.17 ± 1.35abc
Serum HDL-C (mmol/L)1.01 ± 0.14 0.26 ± 0.12a0.45 ± 0.23ab0.60 ± 0.16abc
Liver TC (mg/g) 2.54 ± 0.19 4.09 ± 0.75a3.52 ± 0.38a2.55 ± 0.24bc
Liver TG (mg/g) 26.47 ± 6.40 64.04 ± 18.49a40.81 ± 7.63ab30.80 ± 6.21bc

Forty-two apoE KO mice were randomly divided into 3 groups on average, namely, HFD, FO, and FO+ALA-PS. Fourteen wild type C57BL/6 mice were divided into control group. Values are given as means ± SD (). a < 0.05 versus the control; b < 0.05 versus the HFD group; c < 0.05 versus the FO group. HFD: high fat diet; FO: HFD + 5% flaxseed oil; FO + ALA-PS: HFD + 2.7% flaxseed oil + 3.3% flaxseed oil ester of plant sterol.
3.4. FO+ALA-PS Attenuated Inflammation

Compared to HFD, mice administrated by flaxseed oil had 30.6% and 11.9% less plasma IL-6 and VCAM-1, while this decrease was 56.3% and 29.3% in mice given FO+ALA-PS. In addition, FO+ALA-PS had a significant decline effect on plasma sVCAM-1, TNF-α, and MCP-1 which were initially increased by HFD but not diminished by flaxseed oil intervention. However, there were no significant differences observed in plasma IL-10 in the four groups (Figure 4). On molecular level, we compared the ability of FO and FO+ALA-PS treatment in modulating aortic inflammation indicators. As shown in Figure 5, FO+ALA-PS was more effective than FO in decreasing mRNA and protein expressions of aortic VCAM-1, TNF-α, MCP-1, and IL-6 elevated by HFD. In an effort to further investigate molecular pathways involved in inflammation induction by HFD and the concomitant protection exerted by FO+ALA-PS on this process, we also examined the impact of FO+ALA-PS on the key inflammatory cytokines in circulating monocytes. The results clearly indicated that MCP-1, interleukin-1 beta (IL-1β), and IL-6 were upregulated in response to HFD, while such an effect was almost completely counteracted by the FO+ALA-PS supplement. However, flaxseed oil added alone only significantly modified the mRNA and protein expression of IL-1β (Figure 6).

3.5. Dietary FO+ALA-PS Inhibited Oxidative Stress

Recently acquired evidence pointed out that oxidative stress is a primary contributor to atherosclerosis. In this experiment, in situ ROS production of aorta was determined. As illustrated in Figures 7(a) and 7(b), high level of ROS in aorta induced by HFD was significantly reduced after exposed to flaxseed oil, and this depression effect was further improved by adding ALA-PS. Moreover, FO+ALA-PS but not FO consumption apparently decreased the concentrations of MDA and elevated the levels of GSH in serum and liver (Figures 7(c)7(f)). To examine the potential molecular signaling pathways of FO+ALA-PS against oxidative stress, the main subunits of nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase contributing to atherosclerosis were detected. In mice given FO+ALA-PS supplemented diet, mRNA and protein expressions of aortic , , , and were apparently less than those of HFD-fed mice (Figure 8).

4. Discussion

Atherosclerotic heart disease prevention is largely attributable to factors that can be altered or prevented by lifestyle modification such as nutritional interventions, cessation of smoking, and regular exercise [19]. Recently, dietary intake of naturally occurring PS has been demonstrated to associate with a lower risk of CVD [20]. Since cardiovascular risk factors such as dyslipidemia, inflammation, and oxidative stress rarely occur in isolation, combined nutritional interventions such as n-3 PUFA and PS may provide greater risk reduction compared to either of the supplements alone. In present study, we observed that FO+ALA-PS exerted better alleviative effect on atherosclerosis in apoE KO mice than single treatment of flaxseed oil, and the underlying molecular mechanisms were related to lipid metabolism, inflammation, and oxidative stress improvement.

Hyperlipidemia is a highly predisposing condition for arteriosclerosis and other cardiovascular diseases [21]. In this study, combined supplementation with flaxseed oil and ALA-PS exhibited synergistic and complementary lipid-lowering effects. These data are supported by other studies showing overall lipid improvement effects of flaxseed oil fortified with phytosterols in rats [22]. To investigate the possible mechanisms by which FO+ALA-PS exerts its hypocholesterolemic and hypotriglyceridemic effects, the key molecules involved in lipid metabolism pathways and atherosclerosis formation were detected in this study.

SREBP-2 and HMGCR play a pivotal role in cholesterol homoeostasis. In detail, transcriptional activity of SREBP-2, a transcription factors governed cholesterol synthesis, is primarily regulated at the posttranscriptional level involving INSIG and SREBP cleavage-activating protein (SCAP). SCAP/SREBP-2 precursor complex retains in the endoplasmic reticulum via sterol-induced interaction of SCAP with INSIG [23]. When cellular cholesterol is of low level, disassociation of SCAP from INSIG frees SCAP/SREBP-2 to the Golgi, where mature SREBP-2 is released by 2-step proteolytic cleavages [24]. Then, the mature SREBP-2 enters the nucleus to induce transcription of its target genes such as HMGCR which mediates the rate-limiting step in cholesterol synthesis [25]. It has been published that dietary β-sitosterol and its oxidation products (SiOP) decreased mRNA expressions of SREBP-2 and HMGCR in hamster given high cholesterol diet [26]. Consistent with this result, in present study, lower mRNA and mature protein expressions of HMGCR and SREBP-2 were observed in FO+ALA-PS group but not in FO group. The FO+ALA-PS supplementation may increase the regulatory cholesterol pool and inhibit the SREBP-2 pathway to downregulate HMGCR expression, which in turn reduce the cholesterol synthesis.

In addition, previous publications illustrated that PPARα and SREBP-1c were important regulators of lipogenic genes in the liver [27, 28]. It has been considered that n-3 PUFA exhibited TG-reducing effects through regulation of PPARα and SREBP-1c, which control hepatic fatty acid (FA) catabolism and synthesis, respectively [29, 30]. Recently Devarshi et al. demonstrated that flaxseed oil diet improved lipid metabolism through upregulating PPARα and downregulating SREBP-1 in s diabetic rats [31]. Meanwhile, aloe vera phytosterols were observed to improve the expression levels of PPAR target genes in the livers of mice with diet-induced obesity [32] and ameliorate obesity-associated metabolic disorders via significantly decreasing hepatic SREBP-1 expression in Zucker diabetic fatty (ZDF) rats [33]. Our study also showed similar data with previous reports showing that FO+ALA-PS elevated mRNA and protein expressions of PPARα and decreased SREBP-1, which may explain the lower concentrations of TG in FO+ALA-PS-treated group compared to HFD-treated group. Since the activations of PPARα and SREBP-1c have been shown to stimulate FA beta-oxidation and TG synthesis, respectively [34, 35], we speculate that increased beta-oxidation of FA and reduced TG synthesis are likely responsible for the TG-lowering effect of FO+ALA-PS. Based on the important lipid modulation role of molecules mentioned above and the results in present study, we suggest that improvement effect of FO+ALA-PS on lipid profiles and atherosclerosis may be linked to regulate HMGCR, SREBPs, and PPARα.

Besides hyperlipidemia, inflammation plays a crucial role in the etiology of atherosclerosis, from development of fatty streaks to plaque rupture and thrombosis. Once activated by stimuli such as oxidized lipoproteins, hypertension, or hyperglycemia, vascular endothelial cells express VCAM-1, which enhances the recruitment and adhesion of monocytes to the endothelium [36]. TNF-α, IL-6, and IL-1β increase VCAM-1 expression and mediate localization and recruitment of monocytes into the subendothelial space [37]. Chemoattractant, such as MCP-1, directly migrates leukocytes into the intima and recruits macrophage to the vessel wall [38]. Such endothelial injury ultimately leads to platelet aggregation and the release of platelet-derived growth factor, which initiates the proliferation of smooth muscle cells (SMCs) in the arterial intima, leading to the formation of atherosclerotic plaque [39]. Since these inflammatory markers have a key role in mediating inflammatory cascades and promoting atherosclerosis formation, the positive impact of dietary FO+ALA-PS on plasma levels, mRNA, and protein expressions of VCAM-1, TNF-α, IL-6, IL-1, and MCP-1 observed in this research supported that better function in atherosclerosis prevention of FO+ALA-PS is at least partly through perfecting inflammatory response. However, previous researches showed that consumption of PS esters of sunflower oil and fish oil had no impact on plasma TNF-α, IL-6, and C-reactive protein in hypercholesterolemic persons [40]. One possibility to explain this discrepancy might be that flaxseed oil supplemented with ALA-PS offers a better anti-inflammatory approach due to the large content of ALA in flaxseed oil because dietary consumption of ALA has been demonstrated to reduce circulating levels of several atherogenic and inflammatory markers, including C-reactive protein, serum amyloid A, IL-6, and soluble VCAM-1 in dyslipidemic patients [41, 42]. On the other hand, previous report showed that high levels of plasma n-3 fatty acids were independently associated with lower levels of proinflammatory markers (IL-6, IL-1ra, TNFα, and C-reactive protein) [43]. Thus, anti-inflammatory effects of FO+ALA-PS described in this study may be also associated with its high ratio of n-3 to n-6 fatty acids.

Furthermore, previous publication also pointed out that chronic and acute overproduction of ROS under pathophysiologic conditions was integral in the development of atherosclerosis [44]. In present research, a pronounced reduction of aorta ROS along with lower concentrate of MDA and higher level of GSH was observed in FO+ALA-PS-fed animals than those in mice on HFD. These results suggested that FO+ALA-PS-mediated prevention of atherosclerosis is closely related with inhibition of oxidative stress. Our data is similar with previous reports that flaxseed oil or PS treatment has an antioxidative function [45, 46]. However, the effects of FO+ALA-PS on oxidative stress and the underlying molecular mechanisms for which are very limitedly reported. In the context of cardiovascular disease, oxidative stress leads to an increased ROS production largely determined by NADPH oxidase, a multicomponent enzyme consisting of four major units: , , , and [47]. Some evidences showed that increased expression of contributed to the process of atherosclerosis and apoE−/− mice lacking had a marked reduction of atherosclerosis in the descending aorta [48, 49]. Here, we demonstrated that FO+ALA-PS treatment reversed mRNA and protein expressions of ,   , and in aorta. These data indicate a mechanism that FO+ALA-PS inhibits aortic NADPH oxidase for ROS reduction and results in protection effects of atherosclerosis.

5. Conclusions

Our data is supportive of the synergistic and complementary effects of flaxseed oil containing ALA-PS on overall lipid, systemic inflammation, and oxidative stress which result in further amelioration in atherosclerosis. This study may provide new insights that dietary flaxseed oil containing ALA-PS therapy may be an ideal alternative or adjunct to pharmacological treatment for maximum cardioprotection in high risk individuals and flaxseed oil might be a good source for plant sterol ester supplementation as well as a good candidate to replace other fats in functional foods.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported by the National Natural Science Foundation of China (31000777) and the BASF Nutrition Asia Research Grant.


  1. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics—2014 update: a report from the American Heart Association,” Circulation, vol. 129, no. 3, pp. e28–e292, 2014. View at: Publisher Site | Google Scholar
  2. A. Kitamura, H. Noda, M. Nakamura et al., “Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS),” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 6, pp. 445–463, 2011. View at: Google Scholar
  3. J. L. Witztum and D. Steinberg, “Role of oxidized low density lipoprotein in atherogenesis,” The Journal of Clinical Investigation, vol. 88, no. 6, pp. 1785–1792, 1991. View at: Publisher Site | Google Scholar
  4. M. B. Madsen, A.-M. Jensen, and E. B. Schmidt, “The effect of a combination of plant sterol-enriched foods in mildly hypercholesterolemic subjects,” The American Journal of Clinical Nutrition, vol. 26, no. 6, pp. 792–798, 2007. View at: Publisher Site | Google Scholar
  5. Expert Panel on Detection-Evaluation- and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” JAMA, vol. 285, no. 19, pp. 2486–2497, 2001. View at: Publisher Site | Google Scholar
  6. European Atherosclerosis Society Consensus Panel on Phytosterols, “European Atherosclerosis Society Consensus Panel on Phytosterols, Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease,” Atherosclerosis, vol. 232, no. 2, pp. 346–360, 2014. View at: Google Scholar
  7. D. R. Chirovsky, V. Fedirko, Y. Cui, V. Sazonov, and P. Barter, “Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, no. 4, pp. 404–423, 2009. View at: Publisher Site | Google Scholar
  8. A. Morrison and J. E. Hokanson, “The independent relationship between triglycerides and coronary heart disease,” Vascular Health and Risk Management, vol. 5, no. 1, pp. 89–95, 2009. View at: Google Scholar
  9. I. Demonty, N. Ebine, X. Jia, and P. J. H. Jones, “Fish oil fatty acid esters of phytosterols alter plasma lipids but not red blood cell fragility in hamsters,” Lipids, vol. 40, no. 7, pp. 695–702, 2005. View at: Publisher Site | Google Scholar
  10. M. Noakes, P. M. Clifton, A. M. E. Doornbos, and E. A. Trautwein, “Plant sterol ester-enriched milk and yoghurt effectively reduce serum cholesterol in modestly hypercholesterolemic subjects,” European Journal of Nutrition, vol. 44, no. 4, pp. 214–222, 2005. View at: Publisher Site | Google Scholar
  11. D. Hanke, P. Zahradka, S. K. Mohankumar, J. L. Clark, and C. G. Taylor, “A diet high in α-linolenic acid and monounsaturated fatty acids attenuates hepatic steatosis and alters hepatic phospholipid fatty acid profile in diet-induced obese rats,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 89, no. 6, pp. 391–401, 2013. View at: Publisher Site | Google Scholar
  12. D. Rodriguez-Leyva, C. M. Dupasquier, R. McCullough, and G. N. Pierce, “The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid,” The Canadian Journal of Cardiology, vol. 26, no. 9, pp. 489–496, 2010. View at: Publisher Site | Google Scholar
  13. D. Kromhout, E. J. Giltay, and J. M. Geleijnse, “n-3 fatty acids and cardiovascular events after myocardial infarction,” The New England Journal of Medicine, vol. 363, no. 21, pp. 2015–2026, 2010. View at: Publisher Site | Google Scholar
  14. M. H. Moghadasian, B. M. McManus, D. V. Godin, B. Rodrigues, and J. J. Frohlich, “Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action,” Circulation, vol. 99, no. 13, pp. 1733–1739, 1999. View at: Publisher Site | Google Scholar
  15. Y. Nakashima, A. S. Plump, E. W. Raines, J. L. Breslow, and R. Ross, “ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, no. 1, pp. 133–140, 1994. View at: Publisher Site | Google Scholar
  16. D. Qianchun, Z. Pin, H. Qingde et al., “Chemical synthesis of phytosterol esters of polyunsaturated fatty acids with ideal oxidative stability,” European Journal of Lipid Science and Technology, vol. 113, no. 4, pp. 441–449, 2011. View at: Publisher Site | Google Scholar
  17. J. J. Eady, T. Orta, M. F. Dennis, M. R. L. Stratford, and J. H. Peacock, “Glutathione determination by the Tietze enzymatic recycling assay and its relationship to cellular radiation response,” British Journal of Cancer, vol. 72, no. 5, pp. 1089–1095, 1995. View at: Publisher Site | Google Scholar
  18. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at: Publisher Site | Google Scholar
  19. S. Yusuf, S. Hawken, S. Ounpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004. View at: Google Scholar
  20. V. Escurriol, M. Cofán, C. Moreno-Iribas et al., “Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort,” The Journal of Lipid Research, vol. 51, no. 3, pp. 618–624, 2010. View at: Publisher Site | Google Scholar
  21. J. G. Canto and A. E. Iskandrian, “Major risk factors for cardiovascular disease: debunking the ‘only 50%’ myth,” The Journal of the American Medical Association, vol. 290, no. 7, pp. 947–949, 2003. View at: Publisher Site | Google Scholar
  22. Q. Deng, X. Yu, J. Xu et al., “Effect of flaxseed oil fortified with vitamin E and phytosterols on antioxidant defense capacities and lipids profile in rats,” Journal of Food Science, vol. 77, no. 6, pp. H135–H140, 2012. View at: Publisher Site | Google Scholar
  23. T. Yang, P. J. Espenshade, M. E. Wright et al., “Crucial step in cholesterol homeostasis: Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER,” Cell, vol. 110, no. 4, pp. 489–500, 2002. View at: Publisher Site | Google Scholar
  24. J. L. Goldstein, R. B. Rawson, and M. S. Brown, “Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis,” Archives of Biochemistry and Biophysics, vol. 397, no. 2, pp. 139–148, 2002. View at: Publisher Site | Google Scholar
  25. K. M. Boberg, J.-E. Akerlund, and I. Bjorkhem, “Effect of sitosterol on the rate-limiting enzymes in cholesterol synthesis and degradation,” Lipids, vol. 24, no. 1, pp. 9–12, 1989. View at: Publisher Site | Google Scholar
  26. Y. T. Liang, W. T. Wong, L. Guan et al., “Effect of phytosterols and their oxidation products on lipoprotein profiles and vascular function in hamster fed a high cholesterol diet,” Atherosclerosis, vol. 219, no. 1, pp. 124–133, 2011. View at: Publisher Site | Google Scholar
  27. A. Castrillo and P. Tontonoz, “Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation,” Annual Review of Cell and Developmental Biology, vol. 20, pp. 455–480, 2004. View at: Publisher Site | Google Scholar
  28. K. N. Maxwell, R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow, “Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice,” Journal of Lipid Research, vol. 44, no. 11, pp. 2109–2119, 2003. View at: Publisher Site | Google Scholar
  29. N. Tanaka, X. Zhang, E. Sugiyama et al., “Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice,” Biochemical Pharmacology, vol. 80, no. 10, pp. 1601–1612, 2010. View at: Publisher Site | Google Scholar
  30. S. D. Clarke, “Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 281, no. 4, pp. G865–G869, 2001. View at: Google Scholar
  31. P. P. Devarshi, N. M. Jangale, A. E. Ghule, S. L. Bodhankar, and A. M. Harsulkar, “Beneficial effects of flaxseed oil and fish oil diet are through modulation of different hepatic genes involved in lipid metabolism in streptozotocin-nicotinamide induced diabetic rats,” Genes and Nutrition, vol. 8, no. 3, pp. 329–342, 2013. View at: Publisher Site | Google Scholar
  32. K. Nomaguchi, M. Tanaka, E. Misawa et al., “Aloe vera phytosterols act as ligands for PPAR and improve the expression levels of PPAR target genes in the livers of mice with diet-induced obesity,” Obesity Research and Clinical Practice, vol. 5, no. 3, pp. e190–e201, 2011. View at: Publisher Site | Google Scholar
  33. E. Misawa, M. Tanaka, K. Nomaguchi et al., “Oral ingestion of Aloe vera phytosterols alters hepatic gene expression profiles and ameliorates obesity-associated metabolic disorders in Zucker diabetic fatty rats,” Journal of Agricultural and Food Chemistry, vol. 60, no. 11, pp. 2799–2806, 2012. View at: Publisher Site | Google Scholar
  34. J. D. Horton, J. L. Goldstein, and M. S. Brown, “SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver,” The Journal of Clinical Investigation, vol. 109, no. 9, pp. 1125–1131, 2002. View at: Publisher Site | Google Scholar
  35. K. Schoonjans, B. Staels, and J. Auwerx, “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation,” Biochimica et Biophysica Acta—Lipids and Lipid Metabolism, vol. 1302, no. 2, pp. 93–109, 1996. View at: Publisher Site | Google Scholar
  36. P. Libby, “Inflammation in atherosclerosis,” Nature, vol. 420, no. 6917, pp. 868–874, 2002. View at: Publisher Site | Google Scholar
  37. P. Libby, “Role of inflammation in atherosclerosis associated with rheumatoid arthritis,” The American Journal of Medicine, vol. 121, no. 10, pp. S21–S31, 2008. View at: Publisher Site | Google Scholar
  38. A. Yadav, V. Saini, and S. Arora, “MCP-1: chemoattractant with a role beyond immunity: a review,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1570–1579, 2010. View at: Publisher Site | Google Scholar
  39. P. Libby, P. M. Ridker, and G. K. Hansson, “Inflammation in atherosclerosis: from pathophysiology to practice,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2129–2138, 2009. View at: Publisher Site | Google Scholar
  40. P. J. H. Jones, I. Demonty, Y. M. Chan, Y. Herzog, and D. Pelled, “Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects,” Lipids in Health and Disease, vol. 6, article 28, 2007. View at: Publisher Site | Google Scholar
  41. L. S. Rallidis, G. Paschos, G. K. Liakos, A. H. Velissaridou, G. Anastasiadis, and A. Zampelas, “Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients,” Atherosclerosis, vol. 167, no. 2, pp. 237–242, 2003. View at: Publisher Site | Google Scholar
  42. L. S. Rallidis, G. Paschos, M. L. Papaioannou et al., “The effect of diet enriched with α-linolenic acid on soluble cellular adhesion molecules in dyslipidaemic patients,” Atherosclerosis, vol. 174, no. 1, pp. 127–132, 2004. View at: Publisher Site | Google Scholar
  43. L. Ferrucci, A. Cherubini, S. Bandinelli et al., “Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 439–446, 2006. View at: Publisher Site | Google Scholar
  44. D. Pastori, R. Carnevale, and P. Pignatelli, “Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?” Internal and Emergency Medicine, vol. 9, no. 2, pp. 123–131, 2014. View at: Publisher Site | Google Scholar
  45. A. A. Baskar, K. S. Al Numair, M. Gabriel Paulraj, M. A. Alsaif, M. A. Muamar, and S. Ignacimuthu, “β-sitosterol prevents lipid peroxidation and improves antioxidant status and histoarchitecture in rats with 1,2-dimethylhydrazine-induced colon cancer,” Journal of Medicinal Food, vol. 15, no. 4, pp. 335–343, 2012. View at: Publisher Site | Google Scholar
  46. N. M. Jangale, P. P. Devarshi, A. A. Dubal et al., “Dietary flaxseed oil and fish oil modulates expression of antioxidant and inflammatory genes with alleviation of protein glycation status and inflammation in liver of streptozotocin-nicotinamide induced diabetic rats,” Food Chemistry, vol. 141, no. 1, pp. 187–195, 2013. View at: Publisher Site | Google Scholar
  47. J. F. Keaney Jr., “Oxidative stress and the vascular wall: NADPH oxidases take center stage,” Circulation, vol. 112, no. 17, pp. 2585–2588, 2005. View at: Publisher Site | Google Scholar
  48. H. Kaneto, N. Katakami, M. Matsuhisa, and T.-A. Matsuoka, “Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis,” Mediators of Inflammation, vol. 2010, Article ID 453892, 11 pages, 2010. View at: Publisher Site | Google Scholar
  49. P. A. Barry-Lane, C. Patterson, M. Van Der Merwe et al., “p47phox is required for atherosclerotic lesion progression in ApoE-/- mice,” The Journal of Clinical Investigation, vol. 108, no. 10, pp. 1513–1522, 2001. View at: Publisher Site | Google Scholar

Copyright © 2015 Hao Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles